Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28773162 | 0.96 | CASP3 (0.42) | CASP3PTPN1MDM4TP53KMT2A | |
| SCHEMBL28773163 | 0.96 | CASP3 (0.42) | CASP3PTPN1MDM4TP53KMT2A | |
| SCHEMBL25657670 | 0.91 | CASP3 (0.39) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL24414076 | 0.90 | CASP3 (0.41) | CASP3PTPN1MDM2MDM4TP53 | |
| SCHEMBL16574598 | 0.90 | CASP3 (0.41) | CASP3PTPN1MDM2MDM4TP53 | |
| SCHEMBL25657685 | 0.90 | MDM2 (0.37) | CASP3PTPN1MDM2MDM4TP53 | |
| SCHEMBL25657688 | 0.89 | MDM2 (0.39) | CASP3PTPN1MDM2MDM4TP53 | |
| SCHEMBL25657672 | 0.89 | CASP3 (0.40) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL25658585 | 0.89 | PTPN1 (0.36) | CASP3PTPN1MDM4TP53KMT2A | |
| SCHEMBL15761355 | 0.88 | MDM4 (0.44) | CASP3PTPN1MDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374045-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CASP3 3906/4885PTPN1 201/4885MDM2 164/4885 |
| US-20230374045-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | IAPP, GPR119, INSR | CASP3 752/4885PTPN1 511/4885MDM2 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.